C-W1OIJocasta Neuroscience
Klotho protein, cognitive health, neurodegeneration
modulatingbiologic
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-W1OI
C-W1OIC-W1OIKlotho protein, cognitive health, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Jocasta Neuroscience Klotho protein, cognitive health, neurodegeneration
Jocasta Neuroscience сосредоточена на терапевтическом потенциале Klotho для улучшения когнитивного старения. Ее собственная синтетическая подкожная формула, JN-0413, описывается как лечение first-in-class и best-in-class. Компания сообщает, что начало испытаний на людях ожидается в 2026 году при условии продолжения производственных работ.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Jocasta Neuroscience — Early mechanism · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic